SCHEMBL24596262

SCHEMBL24596262

COC(=O)c1ncn(Cc2cnn(C)c2)c1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 4/20 0.38
USP2 O75604 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HIF1A Q16665 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
ALDH1A1 P00352 2/20 0.36
PKM P14618 1/20 0.35
PARG Q86W56 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP11B2 P19099 2/20 0.35
HPGD P15428 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596265 0.75 NPSR1 (0.39) MAPK10USP2MEN1KMT2AALDH1A1
SCHEMBL19737998 0.70 NPSR1 (0.43) ALDH1A1SMN1; SMN2TSHR
SCHEMBL29871101 0.68 MEN1 (0.42) MEN1KMT2AHSD17B10ALDH1A1PARG
SCHEMBL24596294 0.68 DUT (0.36) SMN1; SMN2
SCHEMBL29247375 0.67 DGAT1 (0.37) MEN1KMT2AALDH1A1TSHR
SCHEMBL24596177 0.66 GRIN2B (0.40) GRIN2BGRIN1
SCHEMBL24553477 0.66 TSHR (0.48) MEN1KMT2AALDH1A1PARGSMN1; SMN2
SCHEMBL877044 0.66 MEN1 (0.47) MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL28701456 0.64 RAB9A (0.41) ALDH1A1SMN1; SMN2GRIN2B
SCHEMBL4150352 0.64 PKM (0.62) ALDH1A1PKMSMN1; SMN2CYP11B2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A MAPK10 1657/4885USP2 621/4885MEN1 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.